Only Virgin Olive Oil -- Not Common -- Reduced Mortality in Spanish Cohort

This 2022 prospective cohort study of 12,161 Spanish adults, published in the European Journal of Clinical Nutrition, was the first to formally separate the effects of virgin olive oil from common (refined) olive oil on long-term mortality. According to PubMed (DOI), virgin olive oil consumption was associated with 34% lower all-cause mortality and 57% lower cardiovascular mortality -- while common olive oil showed no significant mortality benefit.

Why This Study Matters

The olive oil literature has a persistent ambiguity problem. Across the major prospective cohorts -- PREDIMED is the exception -- studies have treated olive oil as a single category, lumping extra virgin, virgin, and refined (sometimes labeled "common" or "pure") varieties together. The chemical differences between these varieties are substantial. Extra virgin and virgin olive oils retain the polyphenols of the original fruit -- hydroxytyrosol, oleuropein, oleocanthal, and related compounds -- at concentrations typically 5 to 30 times higher than refined olive oils, which are heat-and-solvent-processed in ways that strip most of the phenolic content.

If the cardiovascular and longevity benefits of olive oil track with phenolic content rather than fat type, then mixing the varieties in epidemiological analyses would systematically attenuate the observed effects. This study set out to test that hypothesis in a representative Spanish cohort with a high range of olive oil consumption and validated dietary assessment that distinguished the two varieties.

The result was the clearest variety-specific signal in the olive oil mortality literature to date: virgin olive oil reduced mortality, common olive oil did not.

How It Was Designed

The investigators recruited 12,161 participants representative of the Spanish population aged 18 and older between 2008 and 2010, then followed them through 2019 -- a mean follow-up of 10.7 years yielding 129,272 person-years of observation. Habitual food consumption was collected at baseline through a validated computerized dietary history that specifically differentiated between virgin and common olive oil. This dietary instrument is one of the methodological strengths of the study and is what enables the variety-specific comparison.

The researchers then modeled the association between tertiles of olive oil consumption (for each variety separately) and three outcomes: all-cause mortality, cardiovascular mortality, and cancer mortality. Cox proportional-hazards models adjusted for established confounders including age, sex, body mass index, smoking, physical activity, alcohol intake, and overall dietary quality.

By the end of follow-up, the cohort had recorded 143 cardiovascular deaths and 146 cancer deaths, along with the broader all-cause mortality count needed for the primary analysis.

What They Found

The contrast between virgin and common olive oil was direct and statistically clear:

Outcome and Variety	Hazard Ratio (95% CI)	Risk Reduction	P for Trend
All-cause mortality, virgin OO	0.66 (0.49-0.90)	34% lower	0.040
All-cause mortality, common OO	0.96 (0.75-1.23)	Not significant	0.891
CV mortality, virgin OO	0.43 (0.20-0.91)	57% lower	0.017
CV mortality, common OO	0.88 (0.49-1.60)	Not significant	0.242
Per 10 g/day virgin OO increase	0.91 (0.83-1.00)	9% lower per 10g	--

Green indicates a favorable direction vs. lowest tertile of consumption. Red indicates findings that did not reach statistical significance. Virgin olive oil showed significant mortality reductions; common olive oil did not.

Cancer mortality was not significantly associated with either variety of olive oil in this cohort.

Reading the Results

The findings group into two interpretive threads worth pulling apart.

The variety distinction is biologically plausible. Virgin and extra virgin olive oils retain the polyphenols of the original olive fruit -- hydroxytyrosol, oleuropein, oleocanthal, and others -- at concentrations that range from roughly 100 to over 500 mg/kg. Refined or "common" olive oils are processed to remove acidity and defects through heat, deodorization, and sometimes solvent extraction. That processing strips the great majority of the polyphenols. If the cardiovascular benefit of olive oil comes from polyphenols rather than monounsaturated fat alone, the variety-specific finding is exactly what mechanistic biology would predict.

The dose-response holds. Beyond the categorical comparison, the per-10-gram-per-day analysis showed a 9% lower all-cause mortality for each additional 10 grams of virgin olive oil per day. About one tablespoon of additional virgin olive oil daily was associated with this incremental risk reduction. This dose-response gradient strengthens the inference that virgin olive oil intake carries protective signal independent of overall dietary pattern.

The cardiovascular signal is stronger than the all-cause signal. Virgin olive oil reduced cardiovascular mortality by 57% in the top tertile versus the bottom, more than the 34% all-cause reduction. This pattern is consistent with the established mechanistic literature on olive polyphenols and cardiovascular biology -- reduction of oxidized LDL, anti-inflammatory effects on vascular endothelium, improvement in HDL function. Cancer mortality showed no association with either variety.

What Didn't Change

The study is observational. Residual confounding by overall diet quality and health-conscious behavior is possible, even with adjustment. Virgin olive oil consumers in Spain may differ systematically from common olive oil consumers in ways that affect mortality beyond the oil itself.

The cardiovascular and cancer death counts (143 and 146 respectively) are modest, which produces wider confidence intervals than would be ideal -- the cardiovascular HR of 0.43 has a 95% CI of 0.20 to 0.91, meaning the true effect could range from 9% to 80% lower. The directional finding is robust; the precise magnitude is less so.

Broader Context

This 2022 analysis fits between two larger pieces of the olive oil mortality literature. The PREDIMED trial (2013, republished 2018 in NEJM) was the first to randomize a defined EVOO intervention against a control diet and demonstrated a 30% reduction in major cardiovascular events. The Guasch-Ferre 2022 Harvard cohort of 92,383 U.S. adults showed 19% lower all-cause mortality with higher olive oil intake but could not separate varieties in its data. The Donat-Vargas analysis fills the gap: it uses observational methodology in a representative Spanish population while preserving the variety distinction that PREDIMED randomized.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day -- a dose readily achievable from regular virgin or extra virgin olive oil consumption but typically not from common or refined varieties at the same volume of intake.

Related Research

Continue exploring olive oil and polyphenol science:

• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality
• Olive Oil and 19% Lower Mortality in 92,383 U.S. Adults Over 28 Years

Source: View the original study on PubMed

Olivea's Dosage

This study identified mortality benefit at daily virgin olive oil intake of about 1.5 tablespoons (the upper tertile), with a continuous benefit gradient of 9% lower all-cause mortality per additional 10 grams per day. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.